Education
About Us
Working with TipRanks
Follow Us
Arcus Biosciences Inc (RCUS)
NYSE:RCUS
RCUS Stock Chart & Stats
$20.37
-$0.04(-0.26%)
At close: 4:00 PM EST
$20.37
-$0.04(-0.26%)
Day’s Range― - ―
52-Week Range$6.50 - $26.40
Previous CloseN/A
Volume107.84K
Average Volume (3M)945.67K
Market Cap
$2.55B
Enterprise Value$1.93B
Total Cash (Recent Filing)$981.00M
Total Debt (Recent Filing)$99.00M
Price to Earnings (P/E)―
Beta1.95
Next Earnings
May 12, 2026EPS Estimate
-0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.89
Shares Outstanding125,349,480
10 Day Avg. Volume1,103,986
30 Day Avg. Volume945,670
Financial Highlights & Ratios
PEG Ratio-1.52
Price to Book (P/B)4.06
Price to Sales (P/S)10.36
P/FCF Ratio-5.29
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue7.80
Enterprise Value/Gross Profit7.97
Enterprise Value/Ebitda-6.12
Forecast
1Y Price Target
$32.00Price Target Upside57.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-4.11
Revenue Forecast (FY)$97.38M
Bulls Say, Bears Say
Bulls Say
Biomarker-driven Patient SelectionCorrelation between suppression of a serum biomarker and clinical benefit supports a mechanism-based strategy to select patients more likely to respond, potentially improving trial outcomes and market uptake.
Clinical EfficacyPhase 1 data indicate notably longer progression-free survival and higher objective response rates versus the only approved HIF‑2α therapy, suggesting superior clinical activity that could support regulatory and commercial positioning.
Dose ValidationIdentification of a well-tolerated, effective daily dose validates the chosen regimen for pivotal studies and reduces late‑stage development uncertainty.
Bears Say
Competitive PressureA larger competitor's advancing HIF‑2 alpha program and expected strong trial results could raise the efficacy benchmark, making patient enrollment and commercial share more difficult to achieve.
Pipeline Concentration RiskDiscontinuation of a late‑stage gastric cancer trial and limited maturity of other programs concentrate company value on a single kidney cancer asset, increasing downside risk if that program fails to confirm benefit.
Safety ConcernsNotable rates of serious adverse events and treatment discontinuations in early data could complicate regulatory review and slow clinician adoption of the drug.
Arcus Biosciences News
RCUS FAQ
What was Arcus Biosciences Inc’s price range in the past 12 months?
Arcus Biosciences Inc lowest stock price was $6.50 and its highest was $26.40 in the past 12 months.
What is Arcus Biosciences Inc’s market cap?
Arcus Biosciences Inc’s market cap is $2.55B.
When is Arcus Biosciences Inc’s upcoming earnings report date?
Arcus Biosciences Inc’s upcoming earnings report date is May 12, 2026 which is in 70 days.
How were Arcus Biosciences Inc’s earnings last quarter?
Arcus Biosciences Inc released its earnings results on Feb 25, 2026. The company reported -$0.89 earnings per share for the quarter, beating the consensus estimate of -$1.106 by $0.216.
Is Arcus Biosciences Inc overvalued?
According to Wall Street analysts Arcus Biosciences Inc’s price is currently Undervalued.
Does Arcus Biosciences Inc pay dividends?
Arcus Biosciences Inc does not currently pay dividends.
What is Arcus Biosciences Inc’s EPS estimate?
Arcus Biosciences Inc’s EPS estimate is -0.98.
How many shares outstanding does Arcus Biosciences Inc have?
Arcus Biosciences Inc has 125,349,480 shares outstanding.
What happened to Arcus Biosciences Inc’s price movement after its last earnings report?
Arcus Biosciences Inc reported an EPS of -$0.89 in its last earnings report, beating expectations of -$1.106. Following the earnings report the stock price went down -3.601%.
Which hedge fund is a major shareholder of Arcus Biosciences Inc?
Currently, no hedge funds are holding shares in RCUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcus Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.00 (57.09% Upside)
$32.00 (57.09% Upside)
Blogger Sentiment
Bullish
RCUS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 334.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 7.0%
Last 30 Days ▼ 7.0%
News Sentiment
Very Bullish
Bullish news 93%
Bearish news 7%
Bearish news 7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
106.17%
12-Months-Change
Fundamentals
Return on Equity
-63.26%
Trailing 12-Months
Asset Growth
36.00%
Trailing 12-Months
Company Description
Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
RCUS Company Deck
RCUS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical momentum for casdatifan — notably improved ORR (45% at 100 mg QD), durable PFS (median 15.1 months in the 100 mg cohort), low primary progression supporting a TKI‑sparing frontline strategy, an efficient ARC‑20 platform enabling rapid cohort expansion, a robust cash balance (~$1.0B) with runway into H2 2028, and near‑term clinic entry of immunology programs. Key risks discussed include an upcoming futility analysis (STAR‑121), a paused/dose‑reduced AstraZeneca volru combination with immune AE considerations, competition from Merck’s belzutifan program, and high ongoing R&D spend that depends on successful enrollment and readouts. On balance, the highlights (clinical differentiation, commercial opportunity, cash runway, and pipeline progress) strongly outweigh the manageable program and competitive risks.View all RCUS earnings summariesRCUS Stock 12 Month Forecast
Average Price Target
$32.00
▲(57.09% Upside)
Technical Analysis
Ownership Overview
29.84% Insiders
11.12% Mutual Funds
34.77% Other Institutional Investors
7.60% Public Companies and
Individual Investors